Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day

Thursday, July 27, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has provided updates regarding its recent FDA Type B meeting, where it received final meeting minutes. The company is focused on its ARCUS-based in vivo gene editing and ex vivo CAR T therapies. Additionally, it is exploring potential partnerships to support its research and development efforts.
Price reaction · baseline $17.55 (2023-07-26 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences received final meeting minutes from the FDA.
  • The company is advancing its in vivo gene editing and CAR T therapies.
  • Potential partnerships are being explored to enhance development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jul. 27, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B

Frequently Asked Questions

What updates did Precision BioSciences provide?

Precision BioSciences announced updates on its recent FDA Type B meeting and potential partnerships.

What therapies is Precision BioSciences developing?

The company is developing ARCUS-based in vivo gene editing and ex vivo CAR T therapies.

What did the FDA meeting entail?

Precision BioSciences received final meeting minutes from its recent Type B meeting with the FDA.

Is Precision BioSciences exploring partnerships?

Yes, the company is exploring potential partnerships to enhance its research and development.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Azer-Cel FDA meeting gene editing CAR T therapies
Last updated: Jul 27, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →